FilingSEC EDGAR424B3
YD Bio Files Prospectus Supplement Including 2026 Interim Financial Results
· SEC accepted
StageFinancial Reporting
Filing content
YD Bio filed a prospectus supplement incorporating its unaudited interim financial statements and management discussion for the six months ended June 30, 2026.
AI summary of the filing. Please also check the source.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…